Acute myeloid leukemia, IDH-mutated
Jump to navigation
Jump to search
Note: these are biomarker-specific regimens for patients with IDH1 or IDH2-mutated AML, please see the main AML page for other regimens.
| Page editor | |
|---|---|
 |
Martin Schoen, MD, MPH Chicago, IL |
8 regimens on this page
8 variants on this page
|
Relapsed or refractory, salvage therapy
Enasidenib monotherapy
| back to top |
Regimen
| FDA-recommended dose |
| Study | Evidence | Efficacy |
|---|---|---|
| Stein et al. 2017 | Phase I/II | ORR: 40% |
This is the dose used in the phase II expansion cohort; enrolled patients were required to have IDH2-mutated advanced myeloid malignancies.
Chemotherapy
- Enasidenib (Idhifa) 100 mg PO once per day
28-day cycles
References
- Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. Epub 2017 Jun 6. link to original article contains verified protocol link to PMC article PubMed